

TITLE: IMMUNOREGULATOR

Inventor: Khan et al.

Serial No.: 09/716,777

Docket No.: 2183-4618US

1/69




Figure 1.

2/69




Figure 2.

3/69




Figure 3.

4/69




Figure 4.

5/69




Figure 5.

6/69




Figure 6.

7/69




Figure 7.

8/69




Figure 8.




Figure 9.




Figure 10.



9/69




Figure 11.

10/69




Figure 12

11/69




Figure 13

12/69




Figure 14

TITLE: IMMUNOREGULATOR


Inventor: Khan et al.

Serial No.: 09/716,777

Docket No.: 2183-4618US

13/69

Figure 15



14/69






Figure 16

### Figure 17



16/69


Figure 18





17/69

Figure 19



18/69




Figure 20

19/69

**Comparison of Illness Kinetics during Toxic Shock Between NMP and non-NMP treated mice**




Figure 21

20/69




Figure 22

21/69




Figure 23

22/69






Figure 24

23/69



24/69

Figure 26





25/69

superdex peptide, PC3,2/30




Figure 27

26/69




Figure 28.












figure 45






27/69

Figure 29A











28/69

Figure 29B




29/69

Figure 30A









30/69

Figure 30B



31/69

Figure 31



32/69




Figure 32




Figure 34



33/69




Figure 36

34/69




Figure 38




figure 37

35/69




Figure 46.




Figure 47.

36/69




Figure 39

37/69




Figure 43




Figure 44 A.

38/69




Figure 44 B

39/69




Figure 40.




Figure 41




Figure 33.




Figure 35.

40/69




Figure 50




Figure 51




Figure 48




Figure 49




Figure 52




Figure 53



41/69

Mab	Med	IR-P	IR-U	IR-U3-5	IR-U/LMDF
CD1d	4.9	3.2	2.4	2.8	2.8
<b>CD14</b>	0.0	0.6	2.7	1.0	0.8
CD40	0.0	0.0	0.0	0.0	0.0
CD80	0.3	0.0	0.0	0.0	0.0
CD86	1.9	0.8	0.1	0.5	0.6
(all)					
CD95 (all)	5.3	4.1	12.8	5.6	5.6
CD95L	0.2	0.3	0.2	0.0	0.0
<b>ER-MP58</b>	3.9	2.6	1.7	0.0	1.1
<b>F4/80 (all)</b>	39.5	20.1	1.3	2.2	0.0
RB6.8C5		3.6	5.8	5.0	4.1
E-cad	1.9	4.5	0.5	0.5	0.9
(all)					
MHC II	13.8	7.8	9.3	6.3	0.0


Figure54

Mab	Med	IR-P	IR-U	IR-U3-5	IR-U/LMDF
<b>CD1d</b>	4.9	7.0	11.8	9.5	9.5
CD14	0.0	1.0	0.9	1.9	1.2
<b>CD40</b>	0.0	0.6	4.4	5.5	3.8
<b>CD80</b>	0.3	0.3	0.9	0.7	0.6
<b>CD80</b>			8.0	16.0	12.8
(fractie)			(37%)	(20%)	(20%)
<b>CD86</b>	1.9	3.3	19.7	10	11.5
(all)					
<b>CD95</b>	5.3		15.2	16	16
ER-MP58	3.9	5.2	6.1	7.7	7.0
<b>F4/80 (all)</b>	39.5	32.2	108.8	136.9	158.7
RB6.8C5		7.7	8.2	4.0	4.3
E-cad	1.9	2.1	3.2	3.3	1.9
(all)					
<b>MHC II (all)</b>	13.8	18.1	108.8	94.5	109.6

Figure 55

42/69

Figure 56



43/69




Figure 57

44/69




Figure 58

45/69




Figure 59

46/69




Figure 61




Figure 60




Figure 62

47/69




Figure 63

48/69




Figure 64



49/69

NOD/LTJ INVIVO TREATMENT (ANTI-CD3 STIMULATION)




Figure 65

50/69




Figure 66

51/69




Figure 67

52/69




Figure 68

53/69




Figure 70




Figure 69

54/69

Figure 71




Figure 72





Figure 73




Figure 74




Figure 75




Figure 76

55/69




Figure 77




figure 78




Figure 79





Figure 80

56/69


Figure 81

	Before Tx	during Tx	end Tx	Normal (X 10e9
Lymphocytes	0.59	0.75	1.56	1.5 - 4.0
T cell	0.57	0.72	1.48	0.9 - 2.8
CD4	0.24	0.26	0.59	0.5 - 1.7
CD8	0.31	0.41	0.23	0.3 - 0.8
B-cell	0.01	0.01	0.01	0.1 - 0.3

Figure (82a)



(82b)





57/69

Figure 83

	Before Tx	during Tx	end Tx	Normal (X 10e9)
Lymphocytes	2.87	2.06	1.22	1.5 - 4.0
T cell	2.35	1.59	1.02	0.9 - 2.8
CD4	1.95	1.26	0.82	0.5 - 1.7
CD8	0.49	0.37	0.18	0.3 - 0.8
B-cell	0.33	0.19	0.14	0.1 - 0.3




Figure 84




Figure 85

58/69




Figure 86

59/69




Figure 87




Figure 88

60/69




Figure 89




Figure 90




Figure 91

61/69




Figure 92




Figure 93




Figure 94

TITLE: IMMUNOREGULATOR  
Inventor: Khan et al.  
Serial No.: 09/716,777  
Docket No.: 2183-4618US

62/69




Figure 96

TITLE: IMMUNOREGULATOR

Inventor: Khan et al.

Serial No.: 09/716,777

Docket No.: 2183-4618US

63/69





Figure 95

64/69



**Figure 97**



TITLE: IMMUNOREGULATOR

Inventor: Khan et al.

Serial No.: 09/716,777

Docket No.: 2183-4618US

65/69




Figure 98

66/69




Figure 99

67/69





Figure 100

68/69



GPC 60 Å  
Figure 101

69/69




Figure 102